Evaluating subgroups of probands with NAFLD based on ALT/AST values or liver morphology [2] or alcoholic/non-alcoholic fatty liver scores/indices, detecting alleles associated with increased NAFLD risk [15, 16], determining the effects of therapeutic phlebotomy on ALT and AST levels, treating NAFLD, and evaluating of post-diagnosis observations other than QFe were beyond the scope of this work. This evidence concerns the gene GPT and fatty liver disease.